

# Patient Group Direction

For the supply of

**Duac Once Daily<sup>®</sup> gel**

(benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel  
(3% and 1% gel))

(benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel  
(5% and 1% gel))

By pharmacists providing the NHS Wales Clinical Community Pharmacy Service for

the treatment of **acne vulgaris**

in **Powys Teaching Health Board**

Operational from: 1<sup>st</sup> July 2023

Review Date: 31<sup>st</sup> March 2026

Version number: 1.0

*PGD for the supply of Duac Once Daily<sup>®</sup> gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

Reg No: PGD 0219  
Valid From 01/07/2023  
Review Date 31/03/26  
Expiry Date 30/06/2026

**PGD for the supply of Duac Once Daily<sup>®</sup> (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris by pharmacists delivering the Common Ailment Service component of the Clinical Community Pharmacy Service**

Reference: Duac Once Daily<sup>®</sup> gel PGD  
 Version no: 1.0  
 Valid from: 1<sup>st</sup> July 2023  
 Review date: 31<sup>st</sup> March 2026  
 Expiry date: 30<sup>th</sup> June 2026

**Welsh Medicines Advice Service has developed this PGD for local authorisation**

Those using this PGD must ensure that it is authorised by the Local Health Board in which they are operating and signed in section 2 by an appropriate authorising person, relating to the class of person by whom the product is to be supplied, in accordance with the Human Medicines Regulations 2012 (HMR2012)<sup>1</sup>. **THE PGD IS NOT LEGAL OR VALID WITHOUT SIGNED AUTHORISATION IN ACCORDANCE WITH HMR2012 SCHEDULE 16 Part 2.**

Authorising organisations must not *alter*, *amend* or *add* to the *clinical* content of this document. Such action will invalidate the *clinical sign-off* with which it is provided.

As operation of this PGD is the responsibility of service providers, the authorising organisation can decide which staff groups, in keeping with relevant legislation, can work to the PGD.

**INDIVIDUAL PRACTITIONERS MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE WORKING ACCORDING TO IT.**

Practitioners and organisations must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date.

Any queries regarding the clinical content of this PGD should be addressed to: [welshmedicines.information@wales.nhs.uk](mailto:welshmedicines.information@wales.nhs.uk)

**Change history:**

Version number	Change details	Date
1.0	Original PGD template developed	20 <sup>th</sup> December 2022

<sup>1</sup> this includes any relevant amendments to legislation (e.g. [2013 No.235](#), [2015 No.178](#) and [2015 No.323](#)).

*PGD for the supply of Duac Once Daily<sup>®</sup> gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

## 1. PGD development

This PGD has been developed and peer reviewed by an expert panel and approved by the Community Pharmacy Clinical Advisory Group (CPCAG) in accordance with the PGD Policy.

**This section MUST REMAIN when a PGD is adopted by an organisation**

### Expert panel

Name	Position	Designation
Alya Al-Affan	Main author	Formulary and PGD Lead for the Common Ailments Service, Welsh Medicines Advice Service, Cardiff and Vale UHB
Jason Carroll	CPCAG reviewer	Pharmacy Team Leader – Community Services Cwm Taf Morgannwg UHB
Amy David	CPCAG reviewer	Primary Care Pharmacist, Swansea Bay UHB
Dr. Ceri Todd	Medical Reviewer	Group Medical Director, Primary Care, Therapies Service, Swansea Bay UHB

Date CPCAG approval of PGD: 1<sup>st</sup> June 2023

*PGD for the supply of Duac Once Daily<sup>®</sup> gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*  
Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026





Reg No: PGD 0219  
Valid From 01/07/2023  
Review Date 31/03/26  
Expiry Date 30/06/2026

## 2. Organisational authorisations

The PGD is not legally valid until it has had the authorisation of the Local Health Board in which the community pharmacy using it operates.

It is the responsibility of the Local Health Board, to ensure that all legal and governance requirements are met. The Local Health Board accepts governance responsibility for the appropriate use of the PGD.

**Powys Teaching Health Board** authorises this PGD for use by community pharmacies within its area that have been commissioned to provide the Common Ailments Service component of the Clinical Community Pharmacy Service. This authorisation is limited to those pharmacists that meet the requirements set out within the PGD.

Local Health Board approval (legal requirement) as per health board policy			
Role	Name	Sign	Date
Lead Doctor for PTHB	Dr Kate Wright	 DocuSigned by: <i>Kate Wright</i> 1F267952823F473...	9/7/2023
Chief Pharmacist for PTHB	Jacqui Seaton	 DocuSigned by: <i>Jacqui Seaton</i> 71E8089DE3634C4...	9/12/2023
Clinical Governance Lead for PTHB	Amanda Edwards	 DocuSigned by: <i>Amanda Edwards</i> 74A4E51A42E9473...	9/12/2023
Senior Pharmacist Lead for Community Pharmacies, PTHB	Emlyn Pritchard	 DocuSigned by: <i>Emlyn Pritchard</i> EB776BA7283F49B...	9/7/2023

Local enquiries regarding the use of this PGD may be directed to [welshmedicines.information@wales.nhs.uk](mailto:welshmedicines.information@wales.nhs.uk)

[Appendix B](#) provides a practitioner listing sheet. Individual practitioners must be listed by name to work to this PGD. Alternative practitioner listing sheets may be used where appropriate in accordance with local policy, but this should be an individual agreement or a multiple practitioner listing sheet as included at the end of this PGD.

*PGD for the supply of Duac Once Daily® gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*  
 Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026

Reg No: PGD 0219  
 Valid From 01/07/2023  
 Review Date 31/03/26  
 Expiry Date 30/06/2026

### 3. Characteristics of Staff

<b>Qualifications and professional registration</b>	This PGD is for use by pharmacists currently registered with the General Pharmaceutical Council (GPhC).
<b>Additional requirements</b>	<p>Pharmacists must:</p> <ul style="list-style-type: none"> <li>➤ be employed by, or providing services on behalf of a pharmacy listed in the All Wales Pharmacy Database (AWPD) for the Clinical Community Pharmacy Service.</li> <li>➤ be authorised by name as an approved practitioner under the current terms of this Patient Group Direction before working to it by completing <a href="#">Appendix B</a>.</li> <li>➤ be familiar with the medicine and alert to changes in the <a href="#">Summary of Product Characteristics (SmPC)</a>.</li> <li>➤ have access to the Patient Group Direction and associated resources (including the service specification and the clinical guidance document supporting the PGD) and must be competent in the use of PGDs (see <a href="#">NICE Competency framework</a> for health professionals using PGDs).</li> <li>➤ be named in the All Wales Pharmacy Database for the Common Ailment component of the Clinical Community Pharmacy Service.</li> <li>➤ have met the training requirements for the service as set out by HEIW (Health Education and Improvement Wales).</li> <li>➤ be familiar with the <a href="#">British National Formulary (BNF)</a> and <a href="#">SmPC</a> entries for Duac Once Daily® gel.</li> <li>➤ have awareness of the adverse drug reactions associated with Duac Once Daily® gel.</li> </ul> <p><b>The pharmacist must be listed by name, under the current version of this PGD that has been issued by the Local health Board in which area they are operating before working under its authority.</b></p>
<b>Ongoing training and competency</b>	<p>Pharmacists must:</p> <ul style="list-style-type: none"> <li>➤ undertake regular CPD and maintain own level of competence and knowledge in this clinical area to provide the service.</li> <li>➤ be aware of any updates made to the products in the <a href="#">SmPC</a> and <a href="#">BNF</a>.</li> <li>➤ be aware of any updates to relevant national and local guidelines.</li> </ul>

*PGD for the supply of Duac Once Daily® gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

Reg No: PGD 0219  
Valid From 01/07/2023  
Review Date 31/03/26  
Expiry Date 30/06/2026

	<ul style="list-style-type: none"> <li>➤ as registered professionals, be professionally accountable and must work within their competence.</li> </ul> <p>A record of any training and competency assessments undertaken must be maintained.</p>
--	---

#### 4. Clinical condition

<b>Clinical condition or situation to which this PGD applies</b>	For the treatment of acne vulgaris in accordance with the community pharmacy Common Ailment Service (CAS) component of the Clinical Community Pharmacy Service (CCPS).
<b>Criteria for inclusion</b>	<p>Duac Once Daily<sup>®</sup> gel can be supplied to individuals aged 12 years and over, presenting with symptoms of mild to moderate acne provided:</p> <ul style="list-style-type: none"> <li>➤ the individual has no contraindications to Duac Once Daily<sup>®</sup> gel – see <a href="#">SmPC</a></li> <li>➤ where informed consent has been given (patient, parent/guardian, carer)</li> </ul> <p>N.B. Duac Once Daily<sup>®</sup> gel (3% and 1%) should be offered to the individual in the first instance. In case of stock shortages with this strength, Duac Once Daily<sup>®</sup> gel (5% and 1%) can be supplied instead but the individual should be made aware that more irritation may result with the higher strength, particularly in the first few days of use.</p>
<b>Criteria for exclusion<sup>2</sup></b>	<p>Duac Once Daily<sup>®</sup> gel should not be supplied:</p> <ul style="list-style-type: none"> <li>➤ if the pharmacist is unsure of the diagnosis</li> <li>➤ to individuals with severe, extensive or persistent symptoms</li> <li>➤ to individuals with signs of an untreated bacterial, viral or fungal infection of the skin (if infected lesions are present)</li> <li>➤ to individuals presenting with fever, arthralgia or who appear systemically unwell (<u>urgent same day referral</u>)</li> <li>➤ to individuals with mild to moderate acne where a treatment for acne has already been trialled and is ineffective</li> <li>➤ to individuals with moderate to severe acne with a large</li> </ul>

<sup>2</sup> Exclusion under this PGD does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation for supply will be required.

*PGD for the supply of Duac Once Daily<sup>®</sup> gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

(continued over page)	<p>number of inflammatory lesions (especially if there are nodules or cysts present)</p> <ul style="list-style-type: none"> <li>➤ to individuals already receiving acne treatment from a healthcare provider, particularly if the medication is tretinoin, isotretinoin or tazarotene; concomitant application of these with benzoyl peroxide (which is a component of Duac Once Daily<sup>®</sup> gel) may reduce their efficacy and increase irritation</li> <li>➤ if an individual is using an erythromycin containing product as this may antagonise the effects of clindamycin</li> </ul>
<b>Criteria for exclusion</b> (continued)	<ul style="list-style-type: none"> <li>➤ to individuals where oral therapies have previously been used for acne</li> <li>➤ to individuals where other medication the individual is taking may be contributing to acne</li> <li>➤ when acne of any severity is causing or contributing to psychological distress</li> <li>➤ in pregnancy and breastfeeding</li> <li>➤ to individuals with known hypersensitivity to Duac Once Daily<sup>®</sup> gel or any of the excipients – see <a href="#">SmPC</a></li> <li>➤ if the pharmacist is unable to undertake an appropriate assessment, in order to determine the need for the medicine and that it would be appropriate for the patient to use it</li> <li>➤ to individuals who are unable to administer or use the product effectively themselves or who do not have a parent/guardian/carer to administer or apply the medication for them</li> <li>➤ if individual does not agree to share relevant clinical information</li> </ul>
<b>Cautions (including relevant actions to be taken)</b>	<p>Please refer to the <a href="#">SmPC</a> for Duac Once Daily<sup>®</sup> gel for full details of special warnings and precautions for use.</p> <ul style="list-style-type: none"> <li>➤ For external use only.</li> <li>➤ Contact with the mouth, eyes, lips and other mucous membranes or areas of irritated/broken skin should be avoided.</li> <li>➤ Caution should be exercised if application to sensitive areas of skin is considered necessary.</li> </ul>

*PGD for the supply of Duac Once Daily<sup>®</sup> gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

(continued over page)	<ul style="list-style-type: none"> <li>➤ Caution in atopic patients, in whom further skin drying may occur if this gel is used.</li> <li>➤ Avoid other concomitant topical acne therapy, medicated or abrasive soaps and cleansers (including products with high concentrations of alcohol and/or astringents) and soaps or cosmetics that have a strong drying effect because a possible cumulative irritancy may occur. This is sometimes severe, especially with the use of peeling, desquamating or abrasive agents. If severe, local irritancy occurs, Duac Once Daily<sup>®</sup> gel should be discontinued.</li> <li>➤ Caution in individuals with a history of regional enteritis, ulcerative colitis or a history of antibiotic-associated colitis.</li> </ul>
<b>Cautions (including relevant actions to be taken)</b> (continued)	<ul style="list-style-type: none"> <li>➤ Prolonged or significant diarrhoea and/or abdominal cramps may indicate antibiotic-associated colitis, so Duac Once Daily<sup>®</sup> gel should be discontinued immediately and medical advice sought.</li> <li>➤ Antimicrobial resistance may be more dominant in those individuals who have a recent history of systemic or topical clindamycin or erythromycin use.</li> <li>➤ The gel may bleach hair or coloured fabrics so contact with hair, fabrics, furniture and carpeting should be avoided.</li> <li>➤ As benzoyl peroxide can cause increased sensitivity to light, sunlamps should not be used and deliberate/prolonged exposure to sun should be avoided or minimised.</li> </ul> <p>See also <a href="#">drug interactions</a> section below for additional cautions.</p>
<b>Action to be taken if the individual is excluded or declines treatment</b>	<ul style="list-style-type: none"> <li>➤ Explain the reasons for exclusion to the individual and document in the consultation record.</li> <li>➤ If the individual declines, record the reason and advise of the consequences of not receiving treatment. Document the advice given alongside details of any referral made and their (patient, parent, guardian) intended actions.</li> <li>➤ If appropriate, patients may be offered a suitable alternative to Duac Once Daily<sup>®</sup> from the All Wales Common Ailments Service Formulary. Alternatively, refer the individual to their GP if appropriate and/or provide them with information about further options.</li> </ul>

*PGD for the supply of Duac Once Daily<sup>®</sup> gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

	➤ Where there are safeguarding concerns, seek advice from local safeguarding services.
<b>Further advice</b>	➤ Further information can be found in the <a href="#">SmPC</a> , <a href="#">BNF</a> and the <a href="#">All Wales Common Ailments Service Formulary</a> .

## 5. Description of treatment

<b>Name, strength &amp; formulation of drug</b>	Duac Once Daily <sup>®</sup> 10 mg/g + 30 mg/g gel Duac Once Daily <sup>®</sup> 10 mg/g + 50 mg/g gel
<b>Legal category</b>	POM
<b>Black triangle ▼</b>	No
<b>Off-label use</b>	No
<b>Route / method of administration</b>	Topical. For external cutaneous use only.
<b>Dose and frequency of administration</b>	<b>For individuals aged 12 years and over:</b> Apply once daily in the evening, to the entire affected area
<b>Duration of treatment</b>	Up to 12 weeks' treatment. This PGD only allows for the duration stated in the <a href="#">dosage schedule</a> above.
<b>Quantity to be supplied/administered</b>	Once dispensed, Duac Once Daily <sup>®</sup> gel has a shelf-life of 2 months. This means the individual will have to re-present to the pharmacy to obtain the final months' supply. Appropriately labelled pack(s) to provide treatment for 60 days (1 <sup>st</sup> consultation) and 30 days (2 <sup>nd</sup> consultation). <b>1<sup>st</sup> consultation:</b> up to 2 x 30 g packs or 2 x 60 g packs to provide 60 days treatment at a dose of once daily application. <b>2<sup>nd</sup> consultation:</b> up to 1 x 30 g packs or 1 x 60 g packs to provide 30 days treatment at a dose of once daily application.

*PGD for the supply of Duac Once Daily<sup>®</sup> gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

Reg No: PGD 0219  
Valid From 01/07/2023  
Review Date 31/03/26  
Expiry Date 30/06/2026

	<p>N.B. It should be made clear to individuals receiving Duac Once Daily<sup>®</sup> gel that one tube at a time should be opened and prior to use, all tubes should be stored in the fridge.</p> <p>Once in use, the tube can be stored at room temperature or kept in the fridge. The gel will have a 2 month expiry once opened. After this, the tube and any contents should be safely discarded and a new tube opened to complete the 12 week treatment course.</p>
<p><b>Drug interactions</b></p>	<p>No formal drug-drug interaction studies have been performed with Duac Once Daily<sup>®</sup> gel.</p> <p><b>Contraindication</b></p> <ul style="list-style-type: none"> <li>➤ Erythromycin may antagonise the effects of clindamycin - this combination should be avoided.</li> </ul> <p><b>Cautions</b></p> <p>For clindamycin (since systemic absorption can follow topical application, the possibility of interactions should be borne in mind):</p> <ul style="list-style-type: none"> <li>➤ may enhance the action of neuromuscular blocking agents. Caution with concomitant use.</li> <li>➤ cross-resistance may occur with other antibiotics such as lincomycin and erythromycin when using antibiotic monotherapy.</li> </ul> <p><b>Unlikely to be significant</b></p> <ul style="list-style-type: none"> <li>➤ Using topical benzoyl peroxide-containing preparations at the same time as topical sulphonamide-containing products may cause skin and facial hair to temporarily change colour (yellow/orange).</li> </ul> <p>A detailed list of drug interactions can be found in the <a href="#">SmPC</a> and the <a href="#">BNF</a>.</p>
<p><b>Identification &amp; management of adverse reactions</b></p>	<p>A detailed list of adverse reactions is available in the <a href="#">SmPC</a>, and the <a href="#">BNF</a>. This list does not reflect all reported side effects.</p> <p>If the patient experiences any of the following they must discontinue treatment:</p>

*PGD for the supply of Duac Once Daily<sup>®</sup> gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*  
 Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026

(continued over page)	<ul style="list-style-type: none"> <li>➤ difficulty breathing or swallowing</li> <li>➤ swelling of the mouth, face, lips, tongue or throat (severe allergic reaction symptoms)</li> <li>➤ severe itching of the skin, with a rash or raised lumps, hives or blisters</li> </ul>
<b>Identification &amp; management of adverse reactions</b> (continued)	<p>The following side effects have been reported as:</p> <p><u>Very common to common</u> (affecting less than 1 in 10 or between 1 in 10 and 1 in 100 patients)</p> <ul style="list-style-type: none"> <li>➤ Pruritus, burning sensation, dryness, erythema, peeling, dermatitis, photosensitivity reaction, application site pain, headache</li> </ul> <p><u>Uncommon</u> (affecting between 1 in 100 and 1 in 1000 patients)</p> <ul style="list-style-type: none"> <li>➤ Paraesthesia, erythematous rash, worsening of acne</li> </ul> <p><u>Not known</u> (based on post-marketing reports with topical clindamycin/benzoyl peroxide gel)</p> <ul style="list-style-type: none"> <li>➤ Allergic reactions including hypersensitivity and anaphylaxis, colitis, haemorrhagic diarrhoea, diarrhoea, abdominal pain, urticaria, application site reactions including skin discolouration</li> </ul> <p>N.B. detailed lists of adverse reactions are available in the <a href="#">SmPC</a>, and the <a href="#">BNF</a>. Prior to issuing medication, please refer to these resources to check that there has been no change to the potential adverse reactions listed above.</p>
<b>Patient or carer advice/follow up</b>	<p>Supply the marketing authorisation holder's patient information leaflet (<a href="#">PIL</a>).</p> <p><b>How to use:</b></p> <ul style="list-style-type: none"> <li>➤ any make-up worn should be completely removed and the affected area washed; the area should then be rinsed with warm water and gently patted dry.</li> <li>➤ a thin film of gel should be applied on the entire affected area</li> </ul>

*PGD for the supply of Duac Once Daily® gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

(continued over page)	<p>of skin (not just individual spots); the gel should rub in easily-if it doesn't, too much has been used.</p> <ul style="list-style-type: none"> <li>➤ if being used on the face only, the amount of gel to be used at each application is one "finger-tip" unit - this is the amount of gel that reaches from the tip of the finger to the first crease (joint) on the finger.</li> <li>➤ if the gel is being used on the face AND back, the amount of gel to be used at each application is two and a half "finger-tip" units.</li> </ul>
<p><b>Patient or carer advice/follow up</b> (continued)</p>	<ul style="list-style-type: none"> <li>➤ hands should be washed after application of the gel.</li> <li>➤ after gel has dried, non-greasy make-up can be applied to the skin if desired.</li> </ul> <p><b>General advice for individuals/carers regarding treatment with the gel:</b></p> <ul style="list-style-type: none"> <li>➤ if skin is sensitive, start at a lower frequency (e.g. three times per week), increasing to daily as tolerated.</li> <li>➤ avoid applying the gel to the eyes, mouth, angles of nose and mucous membranes, eczematous, broken or sunburned skin.</li> <li>➤ the treatment takes time to work (typically 2– 5 weeks).</li> <li>➤ treatments may cause increased sensitivity to sunlight; avoid too much sun and UV light, and wear sunscreen.</li> <li>➤ if prolonged or significant diarrhoea and/or abdominal cramping occurs in line with the initiation of the gel, the gel should be discontinued immediately as the symptoms may indicate antibiotic-associated colitis - the individual should also be referred to their GP.</li> <li>➤ benzoyl peroxide may bleach hair and coloured fabrics including clothing, towels and bed linen so care to avoid contact of the gel with these materials should be taken; hands should be washed thoroughly after use of the gel.</li> <li>➤ seek medical advice if the acne does not start to improve within 6 weeks, or sooner if it becomes worse.</li> </ul> <p><b>Inform the individual or their carer:</b></p>

*PGD for the supply of Duac Once Daily® gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

(continued over page)	<ul style="list-style-type: none"> <li>➤ avoid over-cleaning the skin (which may cause dryness and irritation).</li> <li>➤ try not to pick or squeeze spots because this usually aggravates them and may cause scarring.</li> <li>➤ use a non-alkaline (skin pH neutral or slightly acidic) synthetic detergent cleansing product twice daily on acne-prone skin.</li> <li>➤ if dry skin is a problem, use a fragrance-free water-based emollient.</li> <li>➤ shower as soon as possible after exercise as sweat can irritate acne.</li> <li>➤ wash hair regularly and avoid letting it fall across the face.</li> <li>➤ avoid using heavy make-up/ cosmetics.</li> </ul>
<b>Patient or carer advice/follow up</b> (continued)	<ul style="list-style-type: none"> <li>➤ avoid oil-based comedogenic skin care products, make-up and sunscreens.</li> <li>➤ If make-up is used, it should be removed at the end of the day.</li> <li>➤ if they get any side effects, to talk to their doctor, or pharmacist or nurse and report any suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) by using the <a href="#">Yellow Card</a> reporting scheme. This includes any possible side effects not listed in the <a href="#">PIL</a>.</li> <li>➤ to seek medical advice in their condition deteriorates and/or they become systemically unwell.</li> <li>➤ to read the <a href="#">PIL</a> before taking the medication.</li> <li>➤ to visit the <a href="#">NHS website</a> on acne for more information.</li> </ul>
<b>Records</b>	<p>The consultation details including any medication supplied under this PGD must be recorded in Choose Pharmacy at the time of the consultation. Where the Choose Pharmacy platform is not available, temporary records must be made using the paper-based consultation record. Paper based records must be transferred into Choose Pharmacy as soon as practically possible following the consultation. If the patient is excluded, a record of the reason for exclusion and any specific advice that has been given must be documented within the consultation notes.</p>

*PGD for the supply of Duac Once Daily® gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

Reg No: PGD 0219  
Valid From 01/07/2023  
Review Date 31/03/26  
Expiry Date 30/06/2026

## Appendices

### Appendix A: Key references

- British National Formulary (BNF) – current edition. Available from: <https://bnf.nice.org.uk/> [accessed 20 March 2023]
- Summary Product Characteristics (SmPC). Available from: <https://www.medicines.org.uk/emc/> [accessed 20 March 2023]
- Patient Group Directions. Medicines practice guideline [MPG2]. Updated March 2017. Available from: <http://www.nice.org.uk/guidance/mpg2/resources> [accessed 20 March 2023]
- General Pharmaceutical Council. In Practice: Guidance on Consent. Revised June 2018. Available from: <https://www.pharmacyregulation.org> [accessed 20 March 2023]
- General Pharmaceutical Council. In Practice: Guidance on Confidentiality. Revised June 2018. Available from: <https://www.pharmacyregulation.org> [accessed 20 March 2023]
- All Wales Medicines Strategy Group. All Wales Common Ailments Formulary. February 2018. Available from: <https://awttc.nhs.wales> [accessed 20 March 2023]
- National Institute for Health and Care Excellence: Clinical Knowledge Summaries. Acne vulgaris. Last revised June 2021. Available from: <https://cks.nice.org.uk> [accessed 02 May 2023]
- Yellow Card Reporting. Available from: <http://yellowcard.mhra.gov.uk> [accessed 20 March 2023]
- NHS 111 Wales Health A-Z. Available from: <https://111.wales.nhs.uk> [accessed 20 March 2023]
- NHS Medicines A-Z. Available from: <https://www.nhs.uk> [accessed 20 March 2023]

*PGD for the supply of Duac Once Daily® gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

Reg No: PGD 0219  
Valid From 01/07/2023  
Review Date 31/03/26  
Expiry Date 30/06/2026

## Appendix B: *Healthcare Professionals Agreement to Practice*

Authorisation for the use of the Patient Group Direction for the supply of:  
Duac Once Daily® gel by community pharmacists under the Clinical Community Pharmacy  
Service, Common Ailment Service (acne vulgaris) commissioned by  
Powys Teaching Health Board

### Patient Group Directions do not remove inherent professional obligations or accountability.

Once completed and approved, health professionals wishing to use the PGD must sign up to the PGD for the local health board in which they will be providing services. Only pharmacists who are accredited in line with the National Service Specification can operate under the PGD.

This Patient Group Direction is to be read, agreed and signed by all registered healthcare professionals authorised to operate the PGD. By signing this document, the professional operating the PGD confirms that they have read and understood the content of this PGD and are willing and competent to work under it within their professional code of conduct. One copy should be given to each named pharmacist and a signed copy must be kept within the pharmacy by the nominated member of staff with responsibility for PGDs. This will usually be the Superintendent Pharmacist or Responsible Pharmacist.

**Name and address of pharmacy:**

#### For registered professional

*I confirm that I have read and understood the content of this PGD and that I am willing and competent to work under it within my professional code of conduct.*

Name of registered pharmacist	Signature	GPhC number	Date

*PGD for the supply of Duac Once Daily® gel (benzoyl peroxide 30 mg/g + clindamycin 10 mg/g gel (3% and 1% gel)) and (benzoyl peroxide 50 mg/g + clindamycin 10 mg/g gel (5% and 1% gel)) for the treatment of acne vulgaris as part of the Community Pharmacy Common Ailment Service*

*Valid from: 1<sup>st</sup> July 2023 Expiry Date: 30<sup>th</sup> June 2026*

Reg No: PGD 0219  
Valid From 01/07/2023  
Review Date 31/03/26  
Expiry Date 30/06/2026